Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC
26/4 18:18
(RTTNews) - Protara Therapeutics Inc.(TARA) announced updated results from its Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in...